Health Care • Biotechnology: Pharmaceutical Preparations
$1.19 ▲ +0.05
(+4.39%)
MKT CAP: $7.8M • VOL: 66.6K
52W L $1 52W H $15
ROARABLE / RQD
D • 47/100
PIOTROSKI
2 / 9
MTVA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$13.7M | -$28.8M | -$15.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$13.0M | -$27.6M | -$12.5M |
| EBITDA (Normalized) | -$13.7M | -$28.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$15.7M | -$24.7M | -$10.8M |
| Capital Expenditures (CapEx) | $2.0K | $8.0K | — |
| Free Cash Flow (FCF) | -$15.7M | -$24.7M | -$10.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $10.3M | $16.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $5.3M | $7.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MTVA.